SG10201508771TA - Deuterium enriched rasagiline - Google Patents
Deuterium enriched rasagilineInfo
- Publication number
- SG10201508771TA SG10201508771TA SG10201508771TA SG10201508771TA SG10201508771TA SG 10201508771T A SG10201508771T A SG 10201508771TA SG 10201508771T A SG10201508771T A SG 10201508771TA SG 10201508771T A SG10201508771T A SG 10201508771TA SG 10201508771T A SG10201508771T A SG 10201508771TA
- Authority
- SG
- Singapore
- Prior art keywords
- deuterium enriched
- rasagiline
- enriched rasagiline
- deuterium
- enriched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
- C07C211/60—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Plant Pathology (AREA)
- Otolaryngology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40674010P | 2010-10-26 | 2010-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201508771TA true SG10201508771TA (en) | 2015-11-27 |
Family
ID=45973513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508771TA SG10201508771TA (en) | 2010-10-26 | 2011-10-25 | Deuterium enriched rasagiline |
| SG2013029293A SG189454A1 (en) | 2010-10-26 | 2011-10-25 | Deuterium enriched rasagiline |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013029293A SG189454A1 (en) | 2010-10-26 | 2011-10-25 | Deuterium enriched rasagiline |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120101168A1 (en) |
| EP (1) | EP2632254A4 (en) |
| JP (1) | JP2014503480A (en) |
| KR (1) | KR20140023872A (en) |
| CN (1) | CN103188933A (en) |
| AU (1) | AU2011320611A1 (en) |
| BR (1) | BR112013010308A2 (en) |
| CA (1) | CA2816104A1 (en) |
| CL (1) | CL2013001101A1 (en) |
| EA (1) | EA201390613A1 (en) |
| IL (1) | IL225852A0 (en) |
| MX (1) | MX2013004598A (en) |
| NZ (1) | NZ610526A (en) |
| SG (2) | SG10201508771TA (en) |
| WO (1) | WO2012058219A2 (en) |
| ZA (1) | ZA201303505B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551481T3 (en) * | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multisystemic atrophy |
| NZ571591A (en) * | 2006-04-03 | 2011-09-30 | Teva Pharma | Use of rasagiline for the treatment of restless legs syndrome |
| AU2007334428B2 (en) * | 2006-12-14 | 2014-05-29 | Teva Pharmaceutical Industries, Ltd. | Crystalline solid rasagiline base |
| EP1987816A1 (en) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate of a rasagiline salt with a water-soluble inactive ingredient |
| CN101909438A (en) * | 2008-01-11 | 2010-12-08 | 泰华制药工业有限公司 | Rasagiline formulations, their preparation and use |
| ES2389353T3 (en) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Rasagiline soft gelatin capsules |
| PL2451771T3 (en) | 2009-07-09 | 2014-12-31 | Ratiopharm Gmbh | Salts of rasagiline and pharmaceutical preparations thereof |
| EP2485722A1 (en) * | 2009-10-09 | 2012-08-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of progressive supranuclear palsy |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-n-propargyl-1-aminoindan |
| CA2806740A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| KR20140090996A (en) | 2011-10-10 | 2014-07-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | R(+)-n-formyl-propargyl-aminoindan |
| BR112014008552A2 (en) | 2011-10-10 | 2017-04-18 | Teva Pharma | r (+) - n-methylpropargylaminoindane |
| BR112015003451A2 (en) | 2012-08-17 | 2017-07-04 | Teva Pharma | parenteral formulation of rasagiline |
| CN111323524B (en) * | 2020-04-08 | 2022-04-15 | 重庆华森制药股份有限公司 | Propargylamine and impurity detection method thereof |
| CN115947675B (en) * | 2022-12-21 | 2024-05-31 | 博济医药科技股份有限公司 | Rasagiline intermediate and preparation method and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US20060018957A1 (en) * | 2004-07-26 | 2006-01-26 | Lerner E I | Pharmaceutical dosage forms including rasagiline |
| ZA200704917B (en) * | 2004-11-24 | 2008-11-26 | Teva Pharma | Rasagiline orally disintegrating compositions |
| WO2006120577A1 (en) * | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| EP1948248A2 (en) * | 2005-11-06 | 2008-07-30 | Katz-Brull, Rachel | Magnetic resonance imaging and spectroscopy means and methods thereof |
| CN102203053B (en) * | 2008-06-02 | 2015-11-25 | 基因里克斯(英国)有限公司 | Improving one's methods for the preparation of amine |
| BRPI0909894A2 (en) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "method of reducing the rate of progression of parkinson's disease in an early stage parkinson's disease patient, method of reducing the rate of progression of parkinson's disease, method of delaying the need for symptomatic antiparkinsonian therapy in a patient of early-stage parkinson's, risk-reduction method for a parkinson's disease patient requiring antiparkinsonian therapy, early-stage parkinson's disease reduction method, functional-decline method for a patient with Parkinson's disease, a patient's treatment method that displays early signs of parkinson's disease, fatigue reduction method in an early-stage parkinson's disease patient, method of reducing the rate of clinical progression, and treatment of symptoms of parkinsonian disease. parkinson in a patient with parkinson's disease, rasagiline or a pharmaceutically acceptable salt of rasagiline, pharmaceutical composition. |
| WO2010054286A2 (en) * | 2008-11-10 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| US20100286124A1 (en) * | 2009-04-10 | 2010-11-11 | Auspex Pharmaceuticals, Inc. | Prop-2-yn-1-amine inhibitors of monoamine oxidase type b |
| WO2011024156A1 (en) * | 2009-08-31 | 2011-03-03 | Brain Watch Ltd. | Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
-
2011
- 2011-10-25 AU AU2011320611A patent/AU2011320611A1/en not_active Abandoned
- 2011-10-25 US US13/281,054 patent/US20120101168A1/en not_active Abandoned
- 2011-10-25 CA CA2816104A patent/CA2816104A1/en not_active Abandoned
- 2011-10-25 CN CN2011800519198A patent/CN103188933A/en active Pending
- 2011-10-25 WO PCT/US2011/057698 patent/WO2012058219A2/en active Application Filing
- 2011-10-25 MX MX2013004598A patent/MX2013004598A/en not_active Application Discontinuation
- 2011-10-25 SG SG10201508771TA patent/SG10201508771TA/en unknown
- 2011-10-25 NZ NZ610526A patent/NZ610526A/en not_active IP Right Cessation
- 2011-10-25 KR KR1020137013167A patent/KR20140023872A/en not_active Application Discontinuation
- 2011-10-25 SG SG2013029293A patent/SG189454A1/en unknown
- 2011-10-25 EP EP11836950.3A patent/EP2632254A4/en not_active Withdrawn
- 2011-10-25 EA EA201390613A patent/EA201390613A1/en unknown
- 2011-10-25 BR BR112013010308A patent/BR112013010308A2/en not_active IP Right Cessation
- 2011-10-25 JP JP2013536727A patent/JP2014503480A/en active Pending
-
2013
- 2013-04-21 IL IL225852A patent/IL225852A0/en unknown
- 2013-04-22 CL CL2013001101A patent/CL2013001101A1/en unknown
- 2013-05-14 ZA ZA2013/03505A patent/ZA201303505B/en unknown
-
2014
- 2014-06-20 US US14/310,321 patent/US20140364506A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201303505B (en) | 2015-08-26 |
| US20140364506A1 (en) | 2014-12-11 |
| AU2011320611A1 (en) | 2013-06-13 |
| CA2816104A1 (en) | 2012-05-03 |
| EP2632254A2 (en) | 2013-09-04 |
| CL2013001101A1 (en) | 2013-09-06 |
| NZ610526A (en) | 2015-10-30 |
| JP2014503480A (en) | 2014-02-13 |
| KR20140023872A (en) | 2014-02-27 |
| CN103188933A (en) | 2013-07-03 |
| EP2632254A4 (en) | 2015-08-05 |
| WO2012058219A3 (en) | 2012-07-26 |
| WO2012058219A2 (en) | 2012-05-03 |
| MX2013004598A (en) | 2013-07-17 |
| EA201390613A1 (en) | 2013-11-29 |
| SG189454A1 (en) | 2013-05-31 |
| BR112013010308A2 (en) | 2016-07-05 |
| US20120101168A1 (en) | 2012-04-26 |
| IL225852A0 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201303505B (en) | Deuterium enriched rasagiline | |
| IL225514A0 (en) | Ornament | |
| HK1225851A1 (en) | Isotope preparation method | |
| HK1200313A1 (en) | Rasagiline citramide | |
| GB2485334B (en) | Structure | |
| AU333439S (en) | Wristband | |
| GB201216392D0 (en) | Multicoordination scheduling | |
| EP2614745A4 (en) | Wristband | |
| SG10201503142SA (en) | Hydroalkylation processes | |
| GB201121846D0 (en) | Sign | |
| EP2591985A4 (en) | Panel-joining structure | |
| GB201222891D0 (en) | Exercise system | |
| GB2482320B (en) | Headgear-mountable respirator | |
| GB201104927D0 (en) | Breathing devices | |
| GB201019676D0 (en) | Sign | |
| HK1209379A1 (en) | Headgear-mountable respirator | |
| TWM388240U (en) | Earring structure | |
| AU4772P (en) | U2 Neotyphodium uncinatum | |
| GB2486217B (en) | Posters | |
| GB201120484D0 (en) | Isotopic labelling or higher organisms | |
| IL229672A0 (en) | Isotopically labeled cdp-choline and uses thereof | |
| AU333206S (en) | Respirator | |
| GB201106037D0 (en) | Enriched stimulation system | |
| GB201014722D0 (en) | Een | |
| GB201012228D0 (en) | sign |